CURRENT INVESTORS
5AM Ventures is a venture capital firm focused on building next-generation life science companies by backing their innovations at their earliest stages. Founded in 2002, 5AM Ventures has more than $400 million under management and is actively investing 5AM Ventures III, L.P., a $200 million fund. The firm has offices in Menlo Park, CA and Waltham, MA.
Formed by successful industry executives and experienced venture capitalists, the 5AM team takes a focused, hands-on approach to company building. In addition to leading investments and contributing as board members of its portfolio companies, 5AM is directly involved in company strategy, business development, and fundraising.
The 5AM portfolio, built on advanced life science technologies, is diversified among innovative platforms, spinouts from established biotechnology and pharmaceutical companies, and companies developing near-term products.
Foundation Medical Partners is a leading national, independent, healthcare venture capital investment firm. Foundation was formed in 2001 with the vision of bringing together cutting edge life science expertise with deep company-building experience. Foundation specializes in early stage investments in the medical device, biopharmaceutical, and predictive medicine technology sectors. Foundation is an active venture investor, providing leadership, support, and strategic resources at every stage in a company's development.
Foundation Medical Partners was an early, active venture investor in many companies that subsequently went public or were acquired in strategic transactions, such as AtriCure (NASDAQ: ATRC), CardioNet (NASDAQ: BEAT), Combinatorx (NASDAQ: CRXX), Immunicon (NASDAQ: IMMC, later acquired by Johnson & Johnson), Northstar Neuroscience (NASDAQ: NSTR, later acquired by St. Jude Medical), and Visiogen (acquired by Abbott), as well as a portfolio of other market-leading privately held firms.
Foundation actively manages over $200 million in venture capital, with a current market capitalization of its healthcare investments totaling over $1.6 billion.
Pangaea Ventures is a venture capital firm that invests in advanced materials, energy, biomedical, and environmental technology companies. With offices located in New Jersey and Vancouver, British Columbia, the company makes investments across the United States and Canada.
Managing two funds at this time, the Pangaea team provides effective support to its portfolio companies with its deep domain knowledge coupled with operational and transactional expertise.
SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care.
SR One has a team of investment professionals, located in the US and Europe. As a Team, their experience spans basic science, industry and the market.
The firm takes an active role in its portfolio companies and works with management teams and fellow venture investors to create significant value. Its current portfolio includes approximately 25 private and public companies and since the firm's founding in 1985, it has invested over $600MM in the biotech space.
SR One's expanded remit also focuses on maximizing the value of GSK technological innovation to establish new businesses and revenue opportunities across a range of industries.
Additional Funding
Semprus BioSciences has also secured funding from the Department of Defense, Department of Energy, National Institutes of Health, and the National Science Foundation.
